Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1237-1247

  De Groote, Mary A ^a   Gilliland, Janet C ^a   Wells, Colby L ^a   Brooks, Elizabeth J ^a   Woolhiser, Lisa K ^a   Gruppo, Veronica ^a   Peloquin, Charles A ^b   Orme, Ian M ^a   Lenaerts, Anne J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IN VIVO CULTURE; MICROBIAL KINETICS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RELAPSE;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; ISONIAZID; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS;

EID: 79952336855     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00595-10     Document Type: Article

References (53)

1. Almeida, D., et al. 2009. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob. Agents Chemother. 53:4178-4184.
2. Andries, K., T. Gevers, and N. Lounis. 2010. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob. Agents Chemother. 54:4540-4544.
3. Anonymous. 2003. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb. Mortal. Wkly. Rep. 52:735-739.
4. Barry, P. J., and T. M. O'Connor. 2007. Novel agents in the management of Mycobacterium tuberculosis disease. Curr. Med. Chem. 14:2000-2008.
5. Bartek, I. L., et al. 2009. The DosR regulon of M. tuberculosis and antibacterial tolerance. Tuberculosis (Edinb.) 89:310-316.
6. Botha, T., and B. Ryffel. 2002. Reactivation of latent tuberculosis by an inhibitor of inducible nitric oxide synthase in an aerosol murine model. Immunology 107:350-357. (Pubitemid 35356955)
7. Cynamon, M. H., and M. Sklaney. 2003. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob. Agents Chemother. 47:2442-2444.
8. Davies, G. R., and E. L. Nuermberger. 2008. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis (Edinb.) 88(Suppl. 1):S65-S74.
9. Dhillon, J., J. M. Dickinson, K. Sole, and D. A. Mitchison. 1996. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob. Agents Chemother. 40:552-555.
10. Dickinson, J. M., V. R. Aber, and D. A. Mitchison. 1977. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 116:627-635.
11. Dorman, S. E., et al. 2009. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 180:273-280.
12. Grosset, J., C. Truffot-Pernot, C. Lacroix, and B. Ji. 1992. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob. Agents Chemother. 36:548-551.
13. Grumbach, F. 1969. Experimental "in vivo" studies of new antituberculosis drugs: capreomycin, ethambutol, rifampicin. Tubercle 50(Suppl.):12-21.
14. Grumbach, F. 1965. Experimental basis for the chemotherapy of tuberculosis. Antimicrob. Agents Chemother. 5:1058-1064.
15. Grumbach, F., G. Canetti, and J. Grosset. 1964. Further experiments on long-term chemotherapy of advanced murine tuberculosis, with emphasis on intermittent regimes. Tubercle 45:125-135.
16. Gruppo, V., et al. 2006. Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 50:1245-1250.
17. Heifets, L. 2002. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51:11-12.
18. Heifets, L., M. Iseman, and P. Lindholm-Levy. 1988. Application of rapid methods (BACTEC system) in clinical mycobacteriology and in the search for new drugs. Bull. Int. Union Tuber. Lung Dis. 63:19.
19. Henao-Tamayo, M. I., et al. 2010. Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis. Clin. Vaccine Immunol. 17:618-625.
20. Ibrahim, M., et al. 2007. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob. Agents Chemother. 51:1011-1015.
21. Ibrahim, M., C. Truffot-Pernot, K. Andries, V. Jarlier, and N. Veziris. 2009. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am. J. Respir. Crit. Care Med. 180:553-557.
22. Kelly, B. P., S. K. Furney, M. T. Jessen, and I. M. Orme. 1996. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:2809-2812.
23. Kubendiran, G., C. N. Paramasivan, S. Sulochana, and D. A. Mitchison. 2006. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis. J. Chemother. 18:617-623.
24. Lecoeur, H. F., P. H. Lagrange, C. Truffot-Pernot, M. Gheorghiu, and J. Grosset. 1989. Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. Clin. Exp. Immunol. 76:458-462.
25. Lenaerts, A. J., P. L. Chapman, and I. M. Orme. 2004. Statistical limitations to the Cornell model of latent tuberculosis infection for the study of relapse rates. Tuberculosis (Edinb.) 84:361-364.
26. Lenaerts, A. J., M. A. Degroote, and I. M. Orme. 2008. Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol. 16:48-54.
27. Lenaerts, A. J., V. Gruppo, J. V. Brooks, and I. M. Orme. 2003. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob. Agents Chemother. 47:783-785.
28. Lenaerts, A. J., et al. 2005. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49:2294-2301.
29. Lenaerts, A. J., C. M. Johnson, K. S. Marrieta, V. Gruppo, and I. M. Orme. 2005. Significant increases in the levels of liver enzymes in mice treated with anti-tuberculosis drugs. Int. J. Antimicrob. Agents 26:152-158.
30. McCune, R. M., F. M. Feldmann, H. P. Lambert, and W. McDermott. 1966. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med. 123:445-468.
31. McCune, R. M., F. M. Feldmann, and W. McDermott. 1966. Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli. J. Exp. Med. 123:469-486.
32. McCune, R. M., Jr., W. McDermott, and R. Tompsett. 1956. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J. Exp. Med. 104:763-802.
33. McCune, R. M., Jr., and R. Tompsett. 1956. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J. Exp. Med. 104:737-762.
34. McDermott, W., R. M. McCune, Jr., and R. Tompsett. 1956. Dynamics of antituberculous chemotherapy. Am. Rev. Tuberc. 74:100-108.
35. Nikonenko, B. V., R. Samala, L. Einck, and C. A. Nacy. 2004. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48:4550-4555.
36. North, R. J., and A. A. Izzo. 1993. Mycobacterial virulence. Virulent strains of Mycobacteria tuberculosis have faster in vivo doubling times and are better equipped to resist growth-inhibiting functions of macrophages in the presence and absence of specific immunity. J. Exp. Med. 177:1723-1733.
37. Nuermberger, E. 2008. Using animal models to develop new treatments for tuberculosis. Semin. Respir. Crit. Care Med. 29:542-551.
38. Nuermberger, E., et al. 2006. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 50:2621-2625.
39. Nuermberger, E., et al. 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother. 52:1522-1524.
40. Nuermberger, E. L., et al. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med. 169:421-426.
41. Nuermberger, E. L., et al. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med. 170:1131-1134.
42. Ordway, D., et al. 2007. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J. Immunol. 179:522-531. (Pubitemid 46986569)
43. Orme, I. M., and F. M. Collins. 1983. Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients. J. Exp. Med. 158:74-83.
44. Rosenthal, I. M., M. Zhang, D. Almeida, J. H. Grosset, and E. L. Nuermberger. 2008. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am. J. Respir. Crit. Care Med. 178:989-993.
45. Rosenthal, I. M., et al. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4:e344.
46. Rullas, J., et al. 2010. Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrob. Agents Chemother. 54:2262-2264.
47. Tyagi, S., et al. 2005. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 49:2289-2293.
48. Veziris, N., et al. 2009. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med. 179:75-79.
49. Veziris, N., N. Lounis, A. Chauffour, C. Truffot-Pernot, and V. Jarlier. 2005. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice. Antimicrob. Agents Chemother. 49:4015-4019.
50. Veziris, N., C. Truffot-Pernot, A. Aubry, V. Jarlier, and N. Lounis. 2003. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob. Agents Chemother. 47:3117-3122.
51. Williams, K. N., et al. 2009. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am. J. Respir. Crit. Care Med. 180:371-376.
52. Williams, K. N., et al. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53:1314-1319.
53. Woolhiser, L. K., D. R. Hoff, K. S. Marietta, I. M. Orme, and A. J. Lenaerts. 2009. Testing of experimental compounds in a relapse model of tuberculosis using granulocyte-macrophage colony-stimulating factor gene-disrupted mice. Antimicrob. Agents Chemother. 53:306-308.